Alpha Compute Corp
ALP · Nasdaq
Share price · ALP
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ALP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 24 Sep 2026+23.6%
Nothing announced by ALP that day or the session before.
- 10 Sep 2026-31.5%
Nothing announced by ALP that day or the session before.
- 3 Sep 2026-35.8%
- 16 Jul 2026-36.1%
Nothing announced by ALP that day or the session before.
- 13 Jul 2026+22.0%
Nothing announced by ALP that day or the session before.
- 26 May 2026+24.1%
Nothing announced by ALP that day or the session before.
- 14 May 2026+23.2%
Nothing announced by ALP that day or the session before.
- 12 May 2026+15.5%
Nothing announced by ALP that day or the session before.
- 24 Apr 2026+18.5%
Nothing announced by ALP that day or the session before.
- 23 Apr 2026-20.4%
Nothing announced by ALP that day or the session before.
Share of unusual movement by asset
For each asset, the share of ALP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 2% |
| Sessions with no dated event | — | 98% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(2 total)
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
January 2027 (2)
What to watch
What to watch
Financial reports
Quarterly & interim (11)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | — | $0.6M | $0.2M | $10M | report ↗ |
View 10 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-Q3 | — | $0.7M | $1.8M | $1.4M-$1.6M operating cash flow | report ↗ |
| 2024-Q2 | — | $1.3M | $3.3M | $1.7M-$1.7M operating cash flow | report ↗ |
| 2023-Q4 | — | $2.8M | $5.3M | $39M-$3.4M operating cash flow | report ↗ |
| 2023-Q3 | — | $4.2M | $3.5M | $5.2M-$4.3M operating cash flow | report ↗ |
| 2023-Q2 | — | $3.6M | $7.7M | $5.9M-$3.5M operating cash flow | report ↗ |
| 2022-Q4 | — | $2.5M | $13M | $7.5M-$2.7M operating cash flow | report ↗ |
| 2022-Q3 | — | $1.6M | $15M | $1.1M-$2.5M operating cash flow | report ↗ |
| 2022-Q2 | — | $1.9M | $21M | $1.6M-$2.2M operating cash flow | report ↗ |
| 2021-Q4 | — | $1.9M | $26M | $4.2M-$1.7M operating cash flow | report ↗ |
| 2021-Q3 | — | $1.3M | $27M | $2.9M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $3.1M | $1.7M | $1.7M-$5.5M operating cash flow | report ↗ |
Portage Biotech reported R&D spend of $3.13M, down 75.0% YoY, cash and equivalents of $1.67M, and a net loss of $6.78M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
Insider transactions
Open-market activity, trailing 12 months: 12 purchases ($315K), 1 sale ($2K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-07 | Villani Fiorenzo · director, See Remarks | Open-market purchase | 5,150 | $3.80 | $20K | Form 4 |
| 2026-09-22 | Villani Fiorenzo · director, See Remarks | Open-market purchase | 10,000 | $4.40 | $44K | Form 4 |
| 2026-09-16 | Villani Fiorenzo · director, See Remarks | Open-market purchase | 4,265 | $4.05 | $17K | Form 4 |
| 2026-09-15 | Villani Fiorenzo · director, See Remarks | Open-market purchase | 10,382 | $4.07 | $42K | Form 4 |
| 2026-09-15 | Villani Fiorenzo · director, See Remarks | Open-market purchase | 7,900 | $4.15 | $33K | Form 4 |
| 2026-09-14 | Mitin Yury · See Remarks | Open-market purchase | 9,000 | $4.29 | $39K | Form 4 |
| 2026-09-14 | Mitin Yury · See Remarks | Open-market sale | 393 | $4.15 | $2K | Form 4 |
| 2026-09-14 | Villani Fiorenzo · director, See Remarks | Open-market purchase | 2,000 | $4.16 | $8K | Form 4 |